Thus, this research not only underscored the significant role of AIMP1 in neurodegenerative disorders, but also proposed that blockade of AIMP1‐CD23 signaling might represent a viable therapeutic approach for the treatment of PD. This evidence concerns the gene FCER2 and Parkinson disease.